In another study on rats, cannabinoids  that included THC, at a dose of 10 mg/kg showed a reduction in inflammation and functional symptoms. The dosage curve followed a bell-shaped pattern.
CBD Oil for Crohn’s
The wide variety of CBD products all come with a detailed third-party Certificate of Analysis of potency and contaminants. Better yet, it is certified by the U.S. Hemp Authority, which issues guidelines on stringent hemp processing. Third-party testing, as for most products on this list, is conducted on all Medterra products.
Established in 2018, Spruce is a CBD brand based in Raleigh, North Carolina. The company prides itself on making American-made CBD products and some of the best CBD oils available.
Medterra manufactures broad-spectrum oil with entourage effects, plus its wide variety of products are all CO2 extracted to yield the best CBD oils for the money.
Researchers mention Aloe Vera as a potential therapeutic agent in treating IBD, based on the positive outcomes of clinical trials on patients with the disease. Other herbs, such as Boswellia serrata and turmeric, are also reported to promote an anti-inflammatory response in the body.
However, these symptoms aren’t chronic in nature; a person with ulcerative colitis may go several months without any symptoms, only to be taken aback by severe flare-ups from time to time.
These recommendations are based on the alleged anti-inflammatory benefits of specific herbs upon consumption.
CBD Dosage for IBD
The disease causes damage to the inner lining of the large intestine, which may lead to frequent bowel movements. Ulcerative colitis commonly affects adults aged thirty to forty years old and generates up to $15 billion government spendings on healthcare in the United States (1).
Some CBD supplements are formulated with herbs such as Aloe Vera, Boswellia serrata, and turmeric. You can also mix different herbal remedies on your own, but we first recommend consulting a doctor knowledgeable about complementary medicine before you start your first trials.
Let’s take a look at these cannabinoids from a more practical point of view.
Researchers hypothesize that CBD may be an effective alternative for ulcerative colitis due to its remarkable anti-inflammatory properties.
The objectives were to assess the efficacy and safety of cannabis and cannabinoids for induction and maintenance of remission in people with CD.
The effects of cannabis and cannabis oil on Crohn’s disease are uncertain. Thus no firm conclusions regarding the efficacy and safety of cannabis and cannabis oil in adults with active Crohn’s disease can be drawn. The effects of cannabis or cannabis oil in quiescent Crohn’s disease have not been investigated. Further studies with larger numbers of participants are required to assess the potential benefits and harms of cannabis in Crohn’s disease. Future studies should assess the effects of cannabis in people with active and quiescent Crohn’s disease. Different doses of cannabis and delivery modalities should be investigated.
What did the researchers find?
The researchers extensively searched the literature up to 17 October 2018 and found three studies (93 participants) that met the inclusion criteria. One ongoing study was also identified. All of the studies were small in size and had some quality issues. One small study (21 participants) compared eight weeks of treatment with cannabis cigarettes containing 115 mg of D9-tetrahydrocannabinol (THC) to placebo cigarettes containing cannabis with the THC removed in participants with active Crohn’s disease who had failed at least one medical treatment. Although no difference in clinical remission rates was observed, more participants in the cannabis group had improvement in their Crohn’s disease symptoms than participants in the placebo group. More side effects were observed in the cannabis cigarette group compared to placebo. These side effects were considered to be mild in nature and included sleepiness, nausea, difficulty with concentration, memory loss, confusion and dizziness. Participants in the cannabis cigarette group reported improvements in pain, appetite and satisfaction with treatment.
Crohn’s disease (CD) is a chronic immune-mediated condition of transmural inflammation in the gastrointestinal tract, associated with significant morbidity and decreased quality of life. The endocannabinoid system provides a potential therapeutic target for cannabis and cannabinoids and animal models have shown benefit in decreasing inflammation. However, there is also evidence to suggest transient adverse events such as weakness, dizziness and diarrhea, and an increased risk of surgery in people with CD who use cannabis.
We searched MEDLINE, Embase, AMED, PsychINFO, the Cochrane IBD Group Specialized Register, CENTRAL, ClinicalTrials.Gov, and the European Clinical Trials Register up to 17 October 2018. We searched conference abstracts, references and we also contacted researchers in this field for upcoming publications.
One small study (N = 22) compared cannabis oil (5% cannabidiol) to placebo oil in people with active CD. This study was rated as high risk of bias for other bias (cannabis participants were more likely than placebo participants to be smokers). There was no difference in clinical remission rates. Forty per cent (4/10) of cannabis oil participants achieved remission at 8 weeks compared to 33% (3/9) of the placebo participants (RR 1.20, 95% CI 0.36 to 3.97; very low certainty evidence). There was no difference in the proportion of participants who had a serious adverse event. Ten per cent (1/10) of participants in the cannabis oil group had a serious adverse event compared to 11% (1/9) of placebo participants (RR 0.90, 95% CI 0.07 to 12.38, very low certainty evidence). Both serious AEs were worsening Crohn’s disease that required rescue intervention. This study did not report on clinical response, CRP, quality of life or withdrawal due to AEs.